DaVita Inc. (NYSE:DVA) Short Interest Update

DaVita Inc. (NYSE:DVA) was the recipient of a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 3,900,000 shares, a decline of 8.9% from the October 31st total of 4,280,000 shares. Based on an average daily trading volume, of 814,700 shares, the days-to-cover ratio is presently 4.8 days. Approximately 5.0% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Several research firms have commented on DVA. UBS Group upped their price target on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Barclays upped their price objective on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Truist Financial upped their price objective on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. Finally, Bank of America upped their price objective on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $161.80.

DaVita Trading Down 0.9 %

Shares of DaVita stock traded down $1.45 during mid-day trading on Monday, hitting $164.72. The stock had a trading volume of 180,823 shares, compared to its average volume of 818,140. The firm has a 50-day moving average of $158.57 and a two-hundred day moving average of $149.48. DaVita has a 12-month low of $103.40 and a 12-month high of $169.51. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. The firm has a market cap of $13.51 billion, a P/E ratio of 17.93, a price-to-earnings-growth ratio of 0.94 and a beta of 0.89.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The company had revenue of $3.26 billion for the quarter, compared to analysts’ expectations of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. The business’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same period in the previous year, the business posted $2.85 EPS. Sell-side analysts forecast that DaVita will post 9.71 earnings per share for the current year.

Insider Activity

In other DaVita news, CEO Javier Rodriguez sold 9,881 shares of the company’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $162.85, for a total value of $1,609,120.85. Following the sale, the chief executive officer now directly owns 887,835 shares of the company’s stock, valued at approximately $144,583,929.75. This represents a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 2.00% of the company’s stock.

Hedge Funds Weigh In On DaVita

A number of hedge funds have recently made changes to their positions in the stock. Transcendent Capital Group LLC acquired a new stake in DaVita during the 3rd quarter worth approximately $25,000. Blue Trust Inc. raised its holdings in shares of DaVita by 58.6% in the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after purchasing an additional 78 shares in the last quarter. Family Firm Inc. acquired a new stake in shares of DaVita in the 2nd quarter valued at $43,000. Versant Capital Management Inc raised its holdings in shares of DaVita by 90.6% in the 2nd quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock valued at $45,000 after purchasing an additional 155 shares in the last quarter. Finally, Friedenthal Financial acquired a new stake in DaVita during the 2nd quarter worth $48,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.